Merck Restructuring Creates New Cancer Unit
Merck restructuring splits human-health into oncology and specialty units as Keytruda nears U.S. exclusivity; investor reaction muted and guidance held.
KEY TAKEAWAYS
- Merck split Human Health into Oncology and Specialty units to sharpen launches and prepare for Keytruda erosion.
- Keytruda had $31.7B 2025 sales; U.S. exclusivity expires 2028 with an estimated $23B gap by 2029.
- Merck maintained 2026 sales guidance of $65.5B-$67.0B, below analyst consensus $67.6B.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Merck & Co. said on Feb. 23, 2026, that it restructured its human-health division into separate oncology and specialty units to sharpen launch execution and prepare for Keytruda’s impending loss of exclusivity. The company maintained its full-year 2026 sales guidance.
New Structure and Leadership
The restructuring splits Merck’s Human Health division into two business units: Oncology, anchored by Keytruda and the oncology pipeline, and Specialty, Pharma & Infectious Diseases. Both units report directly to CEO Robert M. Davis. The change aims to enhance market competitiveness by focusing leadership and commercial resources on the company’s largest growth areas.
Jannie Oosthuizen was named executive vice president and president of Oncology and MSD International, effective immediately. She previously served as senior vice president and president of Merck Human Health U.S. Oosthuizen will oversee coordination of Keytruda and oncology development and launch programs.
Brian Foard will join as executive vice president and president of Specialty, Pharma & Infectious Diseases on March 2, 2026. He was previously an executive vice president at Sanofi. His appointment highlights Merck’s renewed focus on specialty and infectious-disease commercial operations as it prepares multiple product launches.
Keytruda Guidance and Pipeline
Keytruda generated $31.7 billion in 2025 and accounted for about half of Merck’s total sales. The reorganization addresses this revenue concentration by improving how late-stage programs are scaled and launched.
Keytruda’s U.S. patent expires in 2028, creating an estimated $23 billion revenue gap to close by 2029. Industry estimates project top-drug sales falling from $162.8 billion in 2025 to $67 billion by 2029. Management views the split as a defensive move within this broader patent-cliff context.
Merck is advancing roughly 80 Phase III clinical trials—nearly triple its count since 2021—and expects to launch more than 20 new growth drivers. The company projects a cumulative pipeline revenue opportunity exceeding $50 billion by the mid-2030s, assuming successful clinical progress, regulatory approvals, and commercial execution.
A subcutaneous formulation of Keytruda received FDA approval in September 2025 and is expected to extend patent protection beyond 2030. Recent Phase III data from a collaboration with Eisai testing Keytruda plus lenvatinib showed improved progression-free survival. These developments aim to lengthen Keytruda’s commercial runway as Merck prepares new assets.
Merck has bolstered its oncology and infectious-disease capabilities through recent acquisitions, including Harpoon Therapeutics and Cidara, to enhance its pipeline with novel therapeutic modalities.
Management maintained full-year 2026 sales guidance of $65.5 billion to $67.0 billion, below the analyst consensus of $67.6 billion. The company attributed the gap to underestimating patent impacts on legacy products. This guidance sets near-term expectations as Merck restructures to support a wave of anticipated launches.
Investor reaction was muted, with shares largely steady as the company outlined its multi-year plan to offset looming revenue erosion.
